Table 2.
Data used in this study
| Cancer | RR for 20 ng/mL (95% CI) | Lag (years) | Reference |
| Breast (RR from Ref. 11) | 0.60 (0.47, 0.77) | 0 | 58 |
| 0.43 (0.35, 0.54) | 0 | 59 | |
| 0.67 (0.53, 0.85) | 0 | 60 | |
| 0.74 (0.61, 0.89) | 0 | 61 | |
| 0.60 (0.54, 0.67) | 2.67 | 62 | |
| 1.05 (0.83, 1.33) | 3.9 | 63 | |
| 1.02 (0.82, 1.27) | 6.0 | 64 | |
| 0.85 (0.71, 1.01) | 6.5 | 65 | |
| 0.82 (0.65, 1.04) | 7.0 | 66 | |
| Colorectal (RR from Ref. 53) | 0.56 (0.24, 1.30) | 0 | 54 |
| 0.33 (0, 0.93) | 0 | 55 | |
| 0.51 (0.28, 0.71) | 3.85 | 56 | |
| (RR from Ref. 51) | 0.70 (0.41, 1.20) | 9 | 67 |
| 0.55 (0.24, 1.30) | 11 | 68 | |
| 0.37 (0.22, 0.63) | 12 | 40 | |
| 0.69 (0.28, 1.68) | 14 | 57 (M) | |
| 1.21 (0.45, 3.27) | 14 | 57 (F) | |
| 0.93 (0.33, 2.44) | 14 | 57 (M+F) | |
| RR for 10 ng/mL | |||
| Prostate (10 ng/mL) (RR from Ref. 52) | 1.07 (0.81, 1.41) | 4 | 69 |
| 1.05 (0.95, 1.15) | 4 | 70 | |
| 0.86 (0.57, 1.31) | 9 | 71 | |
| 1.05 (0.94, 1.18) | 10 | 72 | |
| 1.14 (0.86, 1.51) | 10 | 73 | |
| 1.25 (0.82, 1.91) | 10 | 74 | |
| 1.20 (1.01, 1.43) | 12 | 74 | |
| 0.76 (0.57, 0.97) | 15 | 72 | |
| 1.13 (0.87, 1.48) | 17 | 75 | |
| 0.89 (0.65, 1.22) | 19 | 76 | |
| 0.96 (0.81, 1.14) | 28 | 77 |
F, females, M, males; RR, relative risk for incremental serum 25(OH)D.